Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.
复制标题

基于PD-1/PD-L1通路阻断的癌症免疫疗法的发展

DOI:
10.1039/c9ra04590b
复制
发表时间:
2019-10-18
期刊:
影响因子:
3.9
通讯作者:
--
中科院分区:
化学3区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

Programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy has achieved considerable success in various tumours. However, only a fraction of patients benefit from its clinical application, and some patients might be suffer from tumour resistance against PD-1/PD-L1 blockade therapy after the original response. In this review, we summarized the main reasons that caused the low response rate of PD-/PD-L1 blockade therapy: firstly, the off-target of PD-1/PD-L1 blocking agents, which is also the main factor of the side effect of autoimmune disorders; secondly, the insufficient infiltration of T cells in a tumour microenvironment; thirdly, the low immunogenicity of tumor cells; fourth, other immunosuppressive components impairing the therapeutic efficacy of the immunotherapy based on the PD-/PD-L1 blockade, and introducing some updated the delivery system of PD-1/PD-L1 blocking agents and the combination therapy based on PD-1/PD-L1 inhibitors and other therapeutics that can complement and promote each other to achieve improved immune response. The possible reasons that caused low response rate and severe side effects of programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy and corresponding strategies.
DOI: 10.1056/nejmoa1003466
发表时间: 2010-08-19
期刊: The New England journal of medicine
影响因子: --
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者: Urba WJ
全细胞癌症疫苗:从自体到同种异体肿瘤和基于树突状细胞的疫苗。
DOI: 10.1007/s00262-008-0536-z
发表时间: 2008-10
影响因子: 5.8
作者:
de Gruijl, Tanja D.;van den Eertwegh, Alfons J. M.;Pinedo, Herbert M.;Scheper, Rik J.
通讯作者: Scheper, Rik J.
透明质酸酶增强基于纳米颗粒的光动力肿瘤治疗
DOI: 10.1021/acs.nanolett.6b00068
发表时间: 2016-04-01
期刊: NANO LETTERS
影响因子: 10.8
作者:
Gong, Hua;Chao, Yu;Liu, Zhuang
通讯作者: Liu, Zhuang
DOI: 10.1111/tid.12025
发表时间: 2013-02-01
影响因子: 2.6
作者:
Dirks, J.;Egli, A.;Hirsch, H. H.
通讯作者: Hirsch, H. H.
DOI: 10.1158/2326-6066.cir-17-0495
发表时间: 2018-04
影响因子: 10.1
作者:
Dougan M;Ingram JR;Jeong HJ;Mosaheb MM;Bruck PT;Ali L;Pishesha N;Blomberg O;Tyler PM;Servos MM;Rashidian M;Nguyen QD;von Andrian UH;Ploegh HL;Dougan SK
通讯作者: Dougan SK